.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
AstraZeneca
Johnson and Johnson
UBS
US Department of Justice
Fuji
Daiichi Sankyo
Covington
Teva
Chubb

Generated: June 26, 2017

DrugPatentWatch Database Preview

Ferric pyrophosphate citrate - Generic Drug Details

« Back to Dashboard

What are the generic sources for ferric pyrophosphate citrate and what is the scope of ferric pyrophosphate citrate freedom to operate?

Ferric pyrophosphate citrate
is the generic ingredient in one branded drug marketed by Rockwell Medical Inc and is included in two NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ferric pyrophosphate citrate has thirty-two patent family members in twenty-one countries.

There are fourteen drug master file entries for ferric pyrophosphate citrate. Two suppliers are listed for this compound.

Summary for Generic Name: ferric pyrophosphate citrate

Tradenames:1
Patents:4
Applicants:1
NDAs:2
Drug Master File Entries: see list14
Suppliers / Packagers: see list2
Clinical Trials: see list628
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:ferric pyrophosphate citrate at DailyMed

Pharmacology for Ingredient: ferric pyrophosphate citrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rockwell Medical Inc
TRIFERIC
ferric pyrophosphate citrate
SOLUTION;IV (INFUSION)206317-001Jan 23, 2015RXYesYes6,779,468► Subscribe ► Subscribe
Rockwell Medical Inc
TRIFERIC
ferric pyrophosphate citrate
SOLUTION;IV (INFUSION)206317-001Jan 23, 2015RXYesYes6,689,275► Subscribe ► Subscribe
Rockwell Medical Inc
TRIFERIC
ferric pyrophosphate citrate
SOLUTION;IV (INFUSION)206317-002Sep 4, 2015RXYesNo► Subscribe► Subscribe
Rockwell Medical Inc
TRIFERIC
ferric pyrophosphate citrate
SOLUTION;IV (INFUSION)206317-001Jan 23, 2015RXYesYes7,816,404► SubscribeY ► Subscribe
Rockwell Medical Inc
TRIFERIC
ferric pyrophosphate citrate
FOR SOLUTION;INTRAVENOUS208551-001Apr 25, 2016RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: ferric pyrophosphate citrate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Rockwell Medical Inc
TRIFERIC
ferric pyrophosphate citrate
SOLUTION;IV (INFUSION)206317-001Jan 23, 20156,689,275► Subscribe
Rockwell Medical Inc
TRIFERIC
ferric pyrophosphate citrate
SOLUTION;IV (INFUSION)206317-001Jan 23, 20156,779,468► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: ferric pyrophosphate citrate

Country Document Number Estimated Expiration
Slovenia2016940► Subscribe
World Intellectual Property Organization (WIPO)9829434► Subscribe
Spain2383713► Subscribe
Japan3955639► Subscribe
Poland191377► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Baxter
Harvard Business School
Accenture
Cerilliant
Fish and Richardson
Dow
Mallinckrodt
UBS
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot